Halcyon V2.0加速器在乳腺癌保乳术后放射治疗的临床应用研究  

Clinical Application of Halcyon V2.0 Accelerator in Postoperative Radiotherapy of Breast Cancer

作　　者：祝鹤龄 杨波[1] 汪之群 张杰[1] 梁永广 孟祥银 周震 祝起禎 张文君 邱杰[1] ZHU Heling;YANG Bo;WANG Zhiqun;ZHANG Jie;LIANG Yongguang;MENG Xiangyin;ZHOU Zhen;ZHU Qizhen;ZHANG Wenjun;QIU Jie(Department of Radiotherapy,Peking Union Medical College Hospital,Beijing 100730,China)

机构地区：[1]北京协和医院放疗科,北京100730

出　　处：《中国医疗设备》2022年第12期63-68,共6页China Medical Devices

基　　金：“十三五”国家重点研发计划项目(2016YFC0105206;2016YFC0105207)。

摘　　要：目的探究使用Halcyon V2.0加速器对乳腺癌保乳术后患者进行规范化放射治疗的临床效果。方法随机选取乳腺癌保乳术后患者41例,依次进行CT模拟定位、靶区和危及器官勾画,根据患者实际情况,对17例患者进行容积弧形调强放射治疗(Volumetric Intensity-Modulated Arc Therapy,VMAT)计划设计,24例患者设计固定野调强放射治疗(Fix Field Intensity-Modulated Radiation Therapy,FF-IMRT)计划。对治疗计划的剂量分布、γ通过率验证、穿射剂量和摆位误差等方面进行分析评估。结果41例患者计划均满足临床治疗标准,VMAT计划的均匀性指数、适形度指数及剂量跌落指数的平均值为0.07、0.90、2.15,FF-IMRT计划的为0.08、0.81、1.96。VMAT计划的Portal Dosimetry面剂量2 mm/2%的3Dγ通过率平均值为99.9%,FF-IMRT计划的为99.6%。VMAT计划治疗中合成野穿射剂量一致性的平均值为86.98%,FF-IMRT计划的为81.31%。结论结果表明,Halcyon V2.0新型环形加速器在乳腺癌保乳术后放疗中,具有较快的执行效率,较好的剂量分布和可靠的计划计算结果,展示出了精准放疗的优势。Objective To explore the clinical effect of standardized radiotherapy with Halcyon V2.0 accelerator in patients with breast cancer after breast conserving surgery.Methods A total of 41 cases of patients with breast cancer after breast conserving were randomly selected,and CT simulation positioning,target area and organs at risk were mapped successively.According to the actual situation of patients,the plan design of volumetric intensity modulated arc therapy(VMAT)was carried out for 17 patients.While 24 patients were designed with fix field intensity-modulated radiation therapy(FF-IMRT).The dose distributions of treatment plans,the plan verifications of 3Dγpassing rate,interfractional in vivo transit dose during treatments,and the setup errors were analyzed and evaluated.Results All 41 plans satisfied the clinical treatment standard.The mean values of homogeneity index,conformity index and gradient index were 0.07,0.90,2.15 for VMAT and 0.08,0.81,1.96 for FF-IMRT.The average passing rate of 3Dγat the dose of 2 mm/2%on the Portal Dosimetry plane was 99.9%for VMAT and 99.6%for FF-IMRT.The mean interfractional in vivo transit dose during treatments was 86.98%for VMAT and 81.31%for FF-IMRT.Conclusion The results show that the new Halcyon V2.0 ring accelerator has fast execution efficiency,good dose distribution and reliable planning calculation results in postoperative radiotherapy for breast cancer,demonstrating the advantages of precision radiotherapy.

关 键 词：Halcyon V2.0加速器 乳腺癌 容积弧形调强 固定野调强 计量学 

分 类 号：R144[医药卫生—公共卫生与预防医学]